A balloon burst during transcatheter mitral valve replacement killed a patient, and Edwards has now pulled four lots of its mitral delivery system from the field, with
FDA flagging the delivery system after the fatality. The device, not the valve, failed:
four lots were recalled after balloon rupture, a failure mode that sits upstream of every durability debate the field is having. Nothing else of consequence published today, which makes the signal louder: transcatheter mitral replacement remains a therapy without a Class I indication anywhere in either the ACC/AHA 2020 or ESC 2025 guidelines, and a delivery-system fatality in that setting tightens the case for surgical repair in anyone who can tolerate a sternotomy. Bench testing in Structural Heart shows mechanical valve rings fracture only at supraphysiologic pressures and pyrolytic carbon rings gain no meaningful diameter, closing the door on hemodynamically useful valve-in-mechanical-valve
procedures. Four consecutive high-risk adults with transposition anatomy underwent systemic AV valve TEER with reduction from 3+ to 1+, a single-center series with no comparator
arm. OPTN's September 2025 Status 2 tightening did not reduce high-priority heart listings; candidates shifted to Status 1 and exception pathways
instead. A 600-patient trial of radial versus femoral secondary access in TAVI moved to active, not recruiting, at Freiburg-Bad
Krozingen. Boston Scientific is down 27% over six months while Medtronic and Abbott both gained roughly 10%, a divergence the October 28
earnings call must explain. What to watch: Abbott reports October 21 with consensus EPS of $1.41, the first read on whether TriClip and MitraClip volumes are tracking the ESC 2025 guideline upgrades.
E. Nolan Beckett, MD · Editor